Skip to main content
Erschienen in:

27.02.2024 | Global Health Services Research

Jeffrey Norton and the Legacy of the Surgical Metabolism Section of the Surgery Branch of the NCI

verfasst von: H. Richard Alexander Jr., MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2024

Einloggen, um Zugang zu erhalten

Excerpt

August 14, 1989 was a typical hot humid summer day in suburban Washington, D.C. I remember the occasional light clouds slowly floating across the blue sky as I made my way to building 31, the National Cancer Institute’s (NCI) headquarters, to start a new position at the National Institutes of Health (NIH) in Bethesda Maryland, a beautiful and at that time, open suburban campus on the outskirts of Washington, D.C. With its manicured grounds and stately buildings, it had the feel and look of a university campus. The surgery branch occupied the second floor of the B-wing of the enormous Warren G. Magnuson Clinical Center, a research hospital that sat at the center of campus and was shared by all the institutes and centers of the NIH for all their clinical or translational research programs and associated clinical activities (Fig. 1). The surgical metabolism section occupied laboratories in two rooms along the B corridor, 2B01 and 2B17, that are memorialized in numerous publications that came out of the section during its 30 years in existence (Fig. 2).
Literatur
2.
Zurück zum Zitat Brennan MF. Uncomplicated starvation versus cancer cachexia. Cancer Res. 1977;37:2359.PubMed Brennan MF. Uncomplicated starvation versus cancer cachexia. Cancer Res. 1977;37:2359.PubMed
3.
Zurück zum Zitat Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med. 1981;305:375–82.CrossRefPubMed Brennan MF. Total parenteral nutrition in the cancer patient. N Engl J Med. 1981;305:375–82.CrossRefPubMed
4.
Zurück zum Zitat Norton JA, Burt ME, Brennan MF. In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer. 1980;45:2934–9.CrossRefPubMed Norton JA, Burt ME, Brennan MF. In vivo utilization of substrate by human sarcoma-bearing limbs. Cancer. 1980;45:2934–9.CrossRefPubMed
5.
Zurück zum Zitat Burt ME, Norton JA, Brennan MF. The human tumor-bearing limb: an ex vivo model. Surgery. 1980;87:128–32.PubMed Burt ME, Norton JA, Brennan MF. The human tumor-bearing limb: an ex vivo model. Surgery. 1980;87:128–32.PubMed
6.
Zurück zum Zitat Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305–15.CrossRefPubMedPubMedCentral Rosenberg SA, Tepper J, Glatstein E, et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg. 1982;196:305–15.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Norton JA, Moley JF, Green MV, et al. Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res. 1985;45:5547–52.PubMed Norton JA, Moley JF, Green MV, et al. Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res. 1985;45:5547–52.PubMed
8.
Zurück zum Zitat Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70.CrossRefPubMedPubMedCentral Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–70.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Cerami A, Ikeda Y, Le Trang N, et al. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett. 1985;11:173–7.CrossRefPubMed Cerami A, Ikeda Y, Le Trang N, et al. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett. 1985;11:173–7.CrossRefPubMed
10.
Zurück zum Zitat Stovroff MC, Fraker DL, Norton JA. Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg. 1989;124:94–9.CrossRefPubMed Stovroff MC, Fraker DL, Norton JA. Cachectin activity in the serum of cachectic, tumor-bearing rats. Arch Surg. 1989;124:94–9.CrossRefPubMed
11.
Zurück zum Zitat Stovroff MC, Fraker DL, Swedenborg JA, Norton JA. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res. 1988;48:4567–72.PubMed Stovroff MC, Fraker DL, Swedenborg JA, Norton JA. Cachectin/tumor necrosis factor: a possible mediator of cancer anorexia in the rat. Cancer Res. 1988;48:4567–72.PubMed
12.
Zurück zum Zitat Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med. 1988;168:95–105.CrossRefPubMed Fraker DL, Stovroff MC, Merino MJ, Norton JA. Tolerance to tumor necrosis factor in rats and the relationship to endotoxin tolerance and toxicity. J Exp Med. 1988;168:95–105.CrossRefPubMed
13.
Zurück zum Zitat Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest. 1991;88:34–9.CrossRefPubMedPubMedCentral Alexander HR, Sheppard BC, Jensen JC, et al. Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J Clin Invest. 1991;88:34–9.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Fraker DL, Langstein HN, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989;170:1015–20.CrossRefPubMed Fraker DL, Langstein HN, Norton JA. Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity. J Exp Med. 1989;170:1015–20.CrossRefPubMed
15.
Zurück zum Zitat Alexander HR, Doherty GM, Buresh CM, et al. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J Exp Med. 1991;173:1029–32.CrossRefPubMed Alexander HR, Doherty GM, Buresh CM, et al. A recombinant human receptor antagonist to interleukin-1 improves survival after lethal endotoxemia in mice. J Exp Med. 1991;173:1029–32.CrossRefPubMed
16.
Zurück zum Zitat Lienard D, Ewalenko P, Delmotti JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60.CrossRefPubMed Lienard D, Ewalenko P, Delmotti JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52–60.CrossRefPubMed
17.
Zurück zum Zitat Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.CrossRefPubMed Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479–89.CrossRefPubMed
18.
Zurück zum Zitat Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416–24.CrossRefPubMed Alexander HR Jr, Bartlett DL, Libutti SK. Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver. Oncologist. 2000;5:416–24.CrossRefPubMed
19.
Zurück zum Zitat Fraker DL, H.R. A, Ross M et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis facotr plus interferon-gamma. Ann Surg Oncol. 2002; S8. Fraker DL, H.R. A, Ross M et al. A phase III trial of isolated limb perfusion for extremity melanoma comparing melphalan alone versus melphalan plus tumor necrosis facotr plus interferon-gamma. Ann Surg Oncol. 2002; S8.
20.
Zurück zum Zitat Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol. 1996;14:479–89.CrossRefPubMed Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a TNF dose escalation study. J Clin Oncol. 1996;14:479–89.CrossRefPubMed
Metadaten
Titel
Jeffrey Norton and the Legacy of the Surgical Metabolism Section of the Surgery Branch of the NCI
verfasst von
H. Richard Alexander Jr., MD
Publikationsdatum
27.02.2024
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2024
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-15078-2

Neu im Fachgebiet Chirurgie

Verbände und Cremes gegen Dekubitus: „Wir wissen nicht, was sie bringen!“

Die Datenlage zur Wirksamkeit von Verbänden oder topischen Mitteln zur Prävention von Druckgeschwüren sei schlecht, so die Verfasser einer aktuellen Cochrane-Studie. Letztlich bleibe es unsicher, ob solche Maßnahmen den Betroffenen nutzen oder schaden.

Nackenschmerzen nach Bandscheibenvorfall: Muskeltraining hilft!

Bei hartnäckigen Schmerzen aufgrund einer zervikalen Radikulopathie schlägt ein Team der Universität Istanbul vor, lokale Steroidinjektionen mit einem speziellen Trainingsprogramm zur Stabilisierung der Nackenmuskulatur zu kombinieren.

US-Team empfiehlt Gastropexie nach Hiatushernien-Op.

Zur Vermeidung von Rezidiven nach Reparatur einer paraösophagealen Hiatushernie sollte einem US-Team zufolge der Magen bei der Op. routinemäßig an der Bauchwand fixiert werden. Das Ergebnis einer randomisierten Studie scheint dafür zu sprechen.

Mit Lidocain kommt der Darm nicht schneller in Schwung

Verzögertes Wiederanspringen der Darmfunktion ist ein Hauptfaktor dafür, wenn Patientinnen und Patienten nach einer Kolonresektion länger als geplant im Krankenhaus bleiben müssen. Ob man diesem Problem mit Lidocain vorbeugen kann, war Thema einer Studie.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.